Press release
OGT Launches New Website Providing Authoritative Resource Aiding Molecular Medicine and Research
Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has launched its brand new website. The new content-rich site provides authoritative insight into the latest developments, tools and issues in genomics research. Intuitive navigation makes it easy for users to find relevant resources matching their requirements, including insightful whitepapers and application notes, discussion topics via the new forum section, as well as detailed information on OGT’s products and services.The new site utilises a totally new webpage design that maximises usability. Particular emphasis has been given to encouraging customer interaction and feedback though the use of discussion boards, opinion polls, social media sharing and the facility to post comments on all articles and news items. All content is connected and indexed ensuring that users always find what they are looking for, while suggesting relevant additional pages to aid user discovery. The unique navigation structure allows users to rapidly select the most relevant research area for their needs from clinical genetics, genomic services and diagnostic biomarkers.
To see what the new site has to offer you, visit www.ogt.co.uk. Also, you could win an Amazon Kindle just by completing our short website survey.
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.
Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high-quality genomic data to customers worldwide. OGT’s CytoSure™ cytogenetics array, labelling and interpretation software products and services provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.
Biomarker Discovery: OGT delivers tailored biomarker discovery solutions that optimise drug and diagnostic development programmes. With expertise in genomic and proteomic diagnostic biomarkers, OGT provides highly specific customised biomarker panels for cancer and other diseases, both for direct sale and also for collaboration with partner companies.
Oxford Gene Technology, Begbroke Science Park, Sandy Lane, Yarnton, Oxford OX5 1PF
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: products@ogt.co.uk
W: www.ogt.co.uk
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release OGT Launches New Website Providing Authoritative Resource Aiding Molecular Medicine and Research here
News-ID: 202680 • Views: …
More Releases from Oxford Gene Technology
OGT Hosts Successful Targeted Sequencing Workshop at ICHG/ASHG 2011
Busy seminar attracts significant interest in OGT’s Genefficiency™ genomic analysis services
Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, recently hosted a highly successful seminar at the International Congress of Human Genetics (ICHG) meeting in Montreal, Canada. The workshop, entitled “Adding value through analysis”, was well attended and outlined how the company’s Genefficiency™ Targeted Sequencing Service can be utilised to deliver rapid…
Oxford Gene Technology and Abcodia form Partnership
Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has today announced a collaborative agreement with Abcodia, a specialist company engaged in the validation and discovery of biomarkers of cancer and other age-related diseases, aimed at improving the early detection of pancreatic cancer. As part of this collaboration, Abcodia will provide access to its large prospective serum biobank, to harness samples taken from…
OGT Appoints New Finance Director
Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has today announced the appointment of a new finance director as part of the company’s ongoing rapid growth and expansion. Mr Tim Hall will join the company at the start of 2012 and brings a strong track record in financial management and strategic planning together with a broad knowledge of the biotech and healthcare…
OGT to Host Workshop at ICHG/ASHG 2011
Seminar will discuss how Targeted Sequencing is being utilised to deliver rapid and cost-effective analysis of human genetic disorders.
Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, will be discussing its new comprehensive targeted sequencing service at the International Congress of Human Genetics (ICHG) meeting in Montreal, Canada (11-15 October 2011). The conference, hosted by the American Society of Human Genetics (ASHG), will…
More Releases for OGT
OGT Hosts Successful Targeted Sequencing Workshop at ICHG/ASHG 2011
Busy seminar attracts significant interest in OGT’s Genefficiency™ genomic analysis services
Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, recently hosted a highly successful seminar at the International Congress of Human Genetics (ICHG) meeting in Montreal, Canada. The workshop, entitled “Adding value through analysis”, was well attended and outlined how the company’s Genefficiency™ Targeted Sequencing Service can be utilised to deliver rapid…
OGT Appoints New Finance Director
Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has today announced the appointment of a new finance director as part of the company’s ongoing rapid growth and expansion. Mr Tim Hall will join the company at the start of 2012 and brings a strong track record in financial management and strategic planning together with a broad knowledge of the biotech and healthcare…
OGT to Host Workshop at ICHG/ASHG 2011
Seminar will discuss how Targeted Sequencing is being utilised to deliver rapid and cost-effective analysis of human genetic disorders.
Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, will be discussing its new comprehensive targeted sequencing service at the International Congress of Human Genetics (ICHG) meeting in Montreal, Canada (11-15 October 2011). The conference, hosted by the American Society of Human Genetics (ASHG), will…
OGT aids research into molecular genetic disease
Unique CytoSure™ Molecular Testing Arrays provide high throughput CNV detection for multiple disorders on a single chip
Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has today announced a new range of CytoSure™ Molecular Testing Arrays and Panels. The new DNA microarrays utilise a unique collection of probes for detecting copy number variations (CNVs) within genes associated with a variety of disorders. Three…
OGT sequencing workshop at ESHG 2011 attracts over 130 delegates
Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, recently announced details of its new targeted sequencing service as part of a workshop at the European Society of Human Genetics Conference (ESHG 2011) in Amsterdam, The Netherlands. The workshop, entitled “Adding value through analysis”, attracted over 130 delegates and featured presentations from OGT team members discussing the key elements of the service. Built…
OGT to develop tumour profiling assay to facilitate personalised cancer treatmen …
Company receives £1.16m award from the UK’s Technology Strategy Board
Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has today announced that it has received a funding award of £1.16 million from the UK government-backed Technology Strategy Board. As part of the project, OGT will develop a tumour profiling assay based on targeted panel enrichment and next generation sequencing (NGS). The new assay…
